Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Inhalational Anthrax”

11 trials

Showing 11 of 11 results

Post-approval studies (Phase 4)Not Yet RecruitingNCT02177721
What this trial is testing

Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure Scenario

Who this might be right for
Infections, Bacterial
Emergent BioSolutions 100
Early research (Phase 1)Study completedNCT00138411
What this trial is testing

Monoclonal Antibody for Treatment of Inhalation Anthrax

Who this might be right for
Bacillus Anthracis (Anthrax)
National Institute of Allergy and Infectious Diseases (NIAID) 36
Early research (Phase 1)Study completedNCT01952444
What this trial is testing

Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers

Who this might be right for
Inhalational Anthrax
Elusys Therapeutics 40
Not applicableNot Yet RecruitingNCT03569553
What this trial is testing

A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients

Who this might be right for
Inhalational Anthrax
Emergent BioSolutions 100
Early research (Phase 1)Study completedNCT01932437
What this trial is testing

Intramuscular Dose-Escalation Study With ETI-204 in Adult Volunteers

Who this might be right for
Inhalational Anthrax
Elusys Therapeutics 36
Large-scale testing (Phase 3)Study completedNCT02016963
What this trial is testing

An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of Raxibacumab With Reinjection

Who this might be right for
Therapeutic Treatment of Inhalation Anthrax
Human Genome Sciences Inc. 20
Early research (Phase 1)Study completedNCT01932242
What this trial is testing

Safety, Tolerability and PK of Repeat Administration of Intravenous ETI-204 in Adult Volunteers

Who this might be right for
Inhalational Anthrax
Elusys Therapeutics 70
Not applicableNot Yet RecruitingNCT07268612
What this trial is testing

Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Prophylaxis of Anthrax Disease.

Who this might be right for
Anthrax
Emergent BioSolutions 250
Early research (Phase 1)Study completedNCT01929226
What this trial is testing

Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers

Who this might be right for
Inhalational Anthrax
Elusys Therapeutics 280
Post-approval studies (Phase 4)UnknownNCT03088111
What this trial is testing

An Open Label Field Study of Anthim (Obiltoxaximab) in Subjects Exposed to B. Anthracis

Who this might be right for
Infection, BacterialAnthrax
Elusys Therapeutics 100
Early research (Phase 1)Study completedNCT00448253
What this trial is testing

Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum

Who this might be right for
Symptoms of Inhalational Anthrax
Emergent BioSolutions 92

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation